ANAPTYSBIO INC's ticker is ANAB and the CUSIP is 032724106. A total of 125 filers reported holding ANAPTYSBIO INC in Q2 2020. The put-call ratio across all filers is 7.78 and the average weighting 0.3%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,595,179 | -12.7% | 200,177 | -1.2% | 0.00% | 0.0% |
| Q2 2023 | $4,120,213 | -43.1% | 202,567 | -39.1% | 0.00% | 0.0% |
| Q1 2023 | $7,236,505 | -31.3% | 332,560 | -2.1% | 0.00% | -50.0% |
| Q4 2022 | $10,526,218 | +22.8% | 339,665 | +1.1% | 0.00% | 0.0% |
| Q3 2022 | $8,574,000 | +24.9% | 336,097 | -0.6% | 0.00% | +100.0% |
| Q2 2022 | $6,863,000 | +2.6% | 338,085 | +25.1% | 0.00% | 0.0% |
| Q1 2022 | $6,687,000 | -31.8% | 270,329 | -4.1% | 0.00% | -50.0% |
| Q4 2021 | $9,798,000 | +25.5% | 281,970 | -2.0% | 0.00% | +100.0% |
| Q3 2021 | $7,807,000 | +0.7% | 287,853 | -3.7% | 0.00% | 0.0% |
| Q2 2021 | $7,754,000 | +53.4% | 299,067 | +27.5% | 0.00% | 0.0% |
| Q1 2021 | $5,056,000 | -9.5% | 234,643 | -9.7% | 0.00% | 0.0% |
| Q4 2020 | $5,587,000 | +39.0% | 259,842 | -4.6% | 0.00% | 0.0% |
| Q3 2020 | $4,018,000 | -37.9% | 272,346 | -6.0% | 0.00% | -50.0% |
| Q2 2020 | $6,473,000 | +48.3% | 289,748 | -6.2% | 0.00% | +100.0% |
| Q1 2020 | $4,364,000 | -13.7% | 308,907 | -0.7% | 0.00% | 0.0% |
| Q4 2019 | $5,056,000 | -52.3% | 311,144 | +2.8% | 0.00% | -66.7% |
| Q3 2019 | $10,593,000 | -29.3% | 302,770 | +14.0% | 0.00% | -25.0% |
| Q2 2019 | $14,983,000 | -20.7% | 265,554 | +2.7% | 0.00% | -20.0% |
| Q1 2019 | $18,883,000 | +15.4% | 258,492 | +0.7% | 0.01% | 0.0% |
| Q4 2018 | $16,369,000 | -29.7% | 256,613 | +9.9% | 0.01% | -16.7% |
| Q3 2018 | $23,294,000 | +55.3% | 233,474 | +10.6% | 0.01% | +50.0% |
| Q2 2018 | $15,000,000 | -27.2% | 211,150 | +6.7% | 0.00% | -20.0% |
| Q1 2018 | $20,605,000 | +7.8% | 197,970 | +4.3% | 0.01% | 0.0% |
| Q4 2017 | $19,117,000 | +333.1% | 189,806 | +50.3% | 0.01% | +400.0% |
| Q3 2017 | $4,414,000 | +207.4% | 126,306 | +110.4% | 0.00% | – |
| Q2 2017 | $1,436,000 | +296.7% | 60,042 | +360.6% | 0.00% | – |
| Q1 2017 | $362,000 | – | 13,037 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 3,688,448 | $102,354,000 | 54.68% |
| Novo Holdings A/S | 3,033,504 | $84,180,000 | 8.96% |
| BVF INC/IL | 1,738,600 | $48,246,000 | 8.21% |
| Cormorant Asset Management, LP | 895,626 | $24,854,000 | 3.61% |
| Perceptive Advisors | 881,957 | $24,474,000 | 1.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 100,500 | $2,789,000 | 1.07% |
| ACUTA CAPITAL PARTNERS, LLC | 165,690 | $4,138,000 | 0.98% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 845,746 | $23,469,000 | 0.90% |
| Iguana Healthcare Management, LLC | 50,000 | $1,388,000 | 0.69% |
| Boxer Capital, LLC | 50,000 | $1,388,000 | 0.30% |